Statins for calcific aortic valve stenosis: Into oblivion after SALTIRE and SEAS? An extensive review from bench to bedside

Current Problems in Cardiology

Volumn 35, Issue 6, 2010, Pages 284-306

  Hermans, Hadewich ^a   Herijgers, Paul ^a   Holvoet, Paul ^a   Verbeken, Eric ^a   Meuris, Bart ^a   Flameng, Willem ^a   Herregods, Marie Christine ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; AZETIDINE DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT;

AORTA VALVE REPLACEMENT; AORTA VALVE STENOSIS; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; EXTRACELLULAR MATRIX; GENETIC PREDISPOSITION; HISTOPATHOLOGY; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; MECHANICAL STRESS; MORTALITY; NONHUMAN; OSSIFICATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIMARY PREVENTION; PROSPECTIVE STUDY; SECONDARY PREVENTION; SHEAR STRESS; TREATMENT RESPONSE; VASCULAR ENDOTHELIUM; ANIMAL; AORTA VALVE; AORTIC VALVE STENOSIS; CALCINOSIS; COMPLICATION; HEART VALVE PROSTHESIS; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANIMALS; ANTICHOLESTEREMIC AGENTS; AORTIC VALVE; AORTIC VALVE STENOSIS; AZETIDINES; CALCINOSIS; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; HEART VALVE PROSTHESIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77952560272     PISSN: 01462806     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpcardiol.2010.02.002     Document Type: Article

References (98)

1. Lindroos M., Kuppari M., Heikkilä J., et al. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol 1993, 21(5):1220-1225.
2. Vahanian A., Baumgartner H., Bax J., et al. Guidelines on the management of valvular heart disease: the Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007, 28(2):230-268.
3. Aronow W.S., Ahn C., Kronzon I., et al. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol 2001, 88(6):693-695.
4. Novaro G.M., Tiong I., Pearce G.L., et al. Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic valve stenosis. Circulation 2001, 104:2205-2209.
5. Bellamy M.F., Pellikka P.A., Klarich K.W., et al. Association of cholesterol levels, hydroxymethylglutaryl coenzyme A reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol 2002, 40:1723-1730.
6. Shavelle D.M., Takasu J., Budoff M.J., et al. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet 2002, 359(9312):1125-1126.
7. Rosenhek R., Rader F., Loho N., et al. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation 2004, 110:1291-1295.
8. Moura L.M., Ramos S.F., Zamorano J.L., et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 2007, 49:554-561.
9. Pohle K., Mäffert R., Ropers D., et al. Progression of aortic valve calcification. Association with coronary atherosclerosis and cardiovascular risk factors. Circulation 2001, 104:1927-1932.
10. Rossebø A.B., Pedersen T., Boman K., et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008, 359:1343-1356.
11. Cowell S.J., Newby D.E., Prescott R.J., et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005, 352:2389-2397.
12. Lindroos M., Kupari M., Valvanne J., et al. Factors associated with calcific aortic valve degeneration in the elderly. Eur Heart J 1994, 15(7):865-870.
13. Stewart B.F., Siscovick D., Lind B.K., et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular health study. J Am Coll Cardiol 1997, 29:630-634.
14. Iung B., Baron G., Butchart E.G., et al. A prospective survey of patients with valvular heart disease in Europe: the Euro heart survey on valvular heart disease. Eur Heart J 2003, 24:1231-1243.
15. Olsson M., Dalsgaard C.J., Haegerstrand A., et al. Accumulation of T-lymphocytes and expression of interleukin-2 receptors in nonrheumatic stenotic aortic valves. J Am Coll Cardiol 1994, 23(5):1162-1170.
16. Otto C.M., Kuusisto J., Reichenbach D.D., et al. Characterization of the early lesion of degenerative valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 1994, 90:844-853.
17. O'Brien K.D., Reichenbach D.D., Marcinova S.M., et al. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of degenerative valvular aortic stenosis. Arterioscler Thromb Vasc Biol 1996, 16:523-532.
18. Rajamannan N.M., Subramaniam M., Springett M., et al. Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation 2002, 105:2660-2665.
19. Simmons C.A., Grant G.R., Manduchi E., et al. Spatial heterogeneity of endothelial phenotypes correlates with site-specific vulnerability to calcification in normal porcine aortic valves. Circ Res 2005, 96:792-799.
20. Vasile E., Antohe F. An ultrastructural study of beta very low density lipoprotein uptake and transport by valvular endothelium of hyperlipidemic rabbits. J Submicrosc Cytol Pathol 1991, 23:279-287.
21. Nievelstein-Post P., Mottino G., Fogelman A., et al. An ultrastructural study of lipoprotein accumulation in cardiac valves of the rabbit. Arterioscler Thromb 1994, 14:1151-1161.
22. Rajamannan N.M., Sangiorgi G., Springett M., et al. Experimental hypercholesterolemia induces apoptosis in the aortic valve. J Heart Valve Dis 2001, 10:371-374.
23. Drolet M.C., Arsenault M., Couet J. Experimental aortic valve stenosis in rabbits. J Am Coll Cardiol 2003, 41:1211-1217.
24. Cimini M., Boughner D.R., Ronald J.A., et al. Development of aortic valve stenosis in a rabbit model of atherosclerosis: an immunohistochemical and histological study. J Heart Valve Dis 2005, 14:365-375.
25. Zeng Z., Nievelstein-Post P., Yin Y., et al. Macromolecular transport in heart valves III: experiment and theory for the size distribution of extracellular liposomes in hyperlipidemic rabbits. Am J Physiol Heart Circ Physiol 2007, 292:H2687-H2697.
26. Luo G., Ducy P., McKee M.D., et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix gla protein. Nature 1997, 386:78-81.
27. Galvin K.M., Donovan M.J., Lynch C.A., et al. A role for SmadVI in development and homeostasis of the cardiovascular system. Nat Genet 2000, 24:171-174.
28. Lee T.C., Zhao Y.D., Courtman D.W., et al. Abnormal aortic development in mice lacking endothelial nitric oxide synthase. Circulation 2000, 101:2345-2348.
29. Tanaka K., Sata M., Fukuda D., et al. Age-associated aortic stenosis in apolipoprotein E-deficient mice. J Am Coll Cardiol 2005, 46:134-141.
30. Garg V., Muth A.N., Ransom J.F., et al. Mutations in NOTCH 1 cause aortic valve disease. Nature 2005, 437:270-274.
31. Drolet M.C., Roussel E., Deshaies Y., et al. A high fat/high carbohydrate diet induces aortic valve disease in C57BL/6J mice. J Am Coll Cardiol 2006, 47:850-855.
32. Weiss R.M., Ohashi M., Miller J.D., et al. Dl. Calcific aortic valve stenosis in old hypercholesterolemic mice. Circulation 2006, 114:2065-2069.
33. Aikawa E., Nahrendorf M., Sosnovik D., et al. Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. Circulation 2007, 115:377-386.
34. Davignon J. Beneficial cardiovascular pleitropic effects of statins. Circulation 2004, 109(suppl III):III-39-III-43.
35. Soini Y., Salo T., Satta J. Angiogenesis is involved in the pathogenesis of nonrheumatic aortic valve stenosis. Hum Pathol 2003, 34(8):756-763.
36. Rajamannan N.M., Subramaniam M., Rickard D., et al. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 2003, 107:2181-2184.
37. Roberts W.C., Ko J.M. Frequency by decades of unicuspid, bicuspid and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated regurgitation. Circulation 2005, 111:920-925.
38. Thubrikar M.J., Aouad J., Nolan S.P. Patterns of calcific deposits in operatively excised stenotic or purely regurgitant aortic valves and their relation to mechanical stress. Am J Cardiol 1986, 58(3):304-308.
39. Nicosia M.A., Cochran R.P., Reichenbach D.R., et al. A coupled fluid-structure finite-element model of the aortic valve and root. J Heart Valve Dis 2003, 12:781-789.
40. Davignon J., Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004, 109(suppl lIII):III-27-III-32.
41. Tiwari R.L., Singh V., Barthwal M.K. Macrophages: an elusive yet emerging therapeutic target of atherosclerosis. Med Res Rev 2008, 28(4):483-544.
42. Robicsek F., Thubrikar M.J., Fokin A.A. Cause of degenerative disease of the trileaflet valve: review of the subject and presentation of a new theory. Ann Thorac Surg 2002, 73:1346-1354.
43. Singh R., Strom J.A., Ondrovic L., et al. Age-related changes in the aortic valve affect leaflet stress distributions: implications for aortic valve degeneration. J Heart Valve Dis 2008, 17(3):290-298.
44. Sacks M.S., Yoganathan A.P. Heart valve function: a biomechanical perspective. Philos Trans R Soc Lond 2007, 362:1369-1391.
45. Balachandran K., Sucosky P., Jo H., et al. Elevated cyclic stretch alters matrix remodelling in aortic valve cusps: implications for degenerative aortic valve disease. Am J Physiol Heart Circ Physiol 2009, 296:H756-H764.
46. Merryman W.D., Lukoff H.D., Long R.A., et al. Synergistic effects of cyclic tension and transforming growth factor -β1 on the aortic valve myofibroblast. Cardiovasc Pathol 2007, 16:268-276.
47. Sucosky P., Balachandran K., Elhammaly A., et al. Altered shear stress stimulates upregulation of endothelial VCAM-1 and ICAM-1 in a BMP-4- and TGFβ1-dependent pathway. Arterioscler Thromb Vasc Biol 2009, 29:254-260.
48. El-Hamamsy I., Balachandran K., Yacoub M.H., et al. Endothelium-dependent regulation of the mechanical properties of aortic valve cusps. J Am Coll Cardiol 2009, 53:1448-1455.
49. Butcher J.T., Penrod A.M., Garcia A.J., et al. Unique morphology and focal adhesion development of valvular endothelial cells in static and fluid flow environments. Arterioscler Thromb Vasc Biol 2004, 24:1429-1434.
50. Butcher J.T., Tressel S., Johnson T., et al. Transcriptional profiles of valvular and vascular endothelial cells reveal phenotypic differences. Influence of shear stress. Arterioscler Thromb Vasc Biol 2006, 26:69-77.
51. Liu A.C., Joag V.R., Gotlieb A.I. The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology. Am J Pathol 2007, 171:1407-1418.
52. Paranya G., Vineberg S., Dvorin E., et al. Aortic valve endothelial cells undergo transforming-growth-factor-β-mediated and non-transforming-growth-factor-β-mediated transdifferentiation in vitro. Am J Pathol 2001, 159:1335-1343.
53. Paruchuri S., Yang J.H., Aikawa E., et al. Human pulmonary valve progenitor cells exhibit endothelial/mesenchymal plasticity in response to vascular endothelial growth factor-A and transforming-growth-factor-β2. Circ Res 2006, 99:861-869.
54. Yip C.Y.Y., Chen J.H., Zhao R., et al. Calcification by valve interstitial cells is regulated by the stiffness of the extracellular matrix. Arterioscler Thromb Vasc Biol 2009, 29:936.
55. Monzack E.L., Gu X., Masters K.S. Efficacy of simvastatin treatment of valvular interstitial cells varies with the extracellular environment. Arterioscler Thromb Vasc Biol 2009, 29:246-253.
56. Wu B., Elmariah S., Kaplan F.S., et al. Paradoxical effects of statins on aortic valve myofibroblasts and osteoblasts. Implications for end-stage valvular heart disease. Arterioscler Thromb Vasc Biol 2005, 25:592-597.
57. Anger T., El-Chafchak J., Habib A., et al. Statins stimulate RGS-regulated ERK 1/2 activation in human calcified and stenotic aortic valves. Exp Mol Pathol 2008, 85:101-111.
58. Edep M.E., Shirani J., Wolf P., et al. Matrix metalloproteinase expression in nonrheumatic aortic stenosis. Cardiovasc Pathol 2000, 9:281-286.
59. Fondard O., Detaint D., Iung B., et al. Extracellular matrix remodeling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors. Eur Heart J 2005, 26:1333-1341.
60. Satta J., Oiva J., Salo T., et al. Evidence for an altered balance between matrix-metalloproteinase-9 and its inhibitors in calcific aortic stenosis. Ann Thorac Surg 2003, 76:681-688.
61. Helske S., Syvaranta S., Lindstedt K.A., et al. Increased expression of elasolytic cathepsins S, K, V and their inhibitor cystatin C in stenotic aortic valves. Arterioscler Thromb Vasc Biol 2006, 26:1791-1798.
62. Helske S., Syvaranta S., Kupari M., et al. Possible role for mast cell-derived cathepsin G in the adverse remodeling of aortic valves. Eur Heart J 2006, 27:1495-1504.
63. Kaden J.J., Dempfle C.E., Grobholz R., et al. Inflammatory regulation of extracellular matrix remodeling in calcific aortic valve stenosis. Cardiovasc Pathol 2005, 14:80-87.
64. Mohty D., Pibarot P., Després J.P., et al. Association between plasma LDL particle size, valvular accumulation of oxidized LDL, and inflammation in patients with aortic stenosis. Arterioscler Thromb Vasc Biol 2008, 28:187-193.
65. Warren B.A., Yong J.L. Calcification of the aortic valve: its progression and grading. Pathology 1997, 29(4):360-368.
66. Chen K., Thomas S.R., Keaney J.F., et al. Oxidation: ROS in vascular signal transduction. Free Radic Biol Med 2003, 35:117-132.
67. Miller J.D., Chu Y., Brooks R.M., et al. Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans. J Am Coll Cardiol 2008, 52:843-850.
68. Liberman M., Bassi E., Martinatti M.K., et al. Oxidant generation predominates around calcifying foci and enhances progression of aortic valve calcification. Arterioscler Thromb Vasc Biol 2008, 28:463-470.
69. Towler D.A. Oxidation, inflammation, and aortic valve calcification. J Am Coll Cardiol 2008, 52:851-854.
70. Maher E.R., Young G., Smyth-Walsh B., et al. Aortic and mitral valve calcification in patients with end-stage renal disease. Lancet 1987, 2(8564):875-877.
71. Ortlepp J.R., Pillich M., Schmitz F., et al. Lower serum calcium levels are associated with greater calcium hydroxyapatite deposition in native aortic valves of male patients with severe calcific aortic stenosis. J Heart Valve Dis 2006, 15(4):502-508.
72. Linhartova K., Veselka J., Sterbakova G., et al. Parathyroid hormone and vitamin D levels are independently associated with calcific aortic stenosis. Circ J 2008, 72:245-250.
73. O'Brien K.D., Kuusisto J., Reichenbach D.D., et al. Osteopontin is expressed in human aortic valvular lesions. Circulation 1995, 92:2163-2168.
74. Mohler E.R., Gannon F., Reynolds C., et al. Bone formation and inflammation in cardiac valves. Circulation 2001, 103:1522-1528.
75. Caira F.C., Stock S.R., Gleason T.G., et al. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein-5 receptor-mediated bone formation. J Am Coll Cardiol 2006, 47:1707-1712.
76. Kaden J.J., Bickelhaupt S., Grobholz R., et al. Receptor activator of nuclear factor kB ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol 2004, 36:57-66.
77. Steinmetz M., Skowasch D., Wernert N., et al. Differential profile of the OPG/RANKL/RANK system in degenerative aortic native and bioprosthetic valves. J Heart Valve Dis 2008, 17(2):187-193.
78. Satta J., Melkko J., Pöllänen R., et al. Progression of human aortic valve stenosis is associated with tenascin-C expression. J Am Coll Cardiol 2002, 39:96-101.
79. Meng X., Ao L., Song Y., et al. Expression of functional toll-like receptors 2 and 4 in human aortic valve interstitial cells: potential roles in aortic valve inflammation and stenosis. Am J Physiol Cell Physiol 2008, 294:C29-C35.
80. Yang X., Fullerton D.A., Su X., et al. Pro-osteogenic phenotype of human aortic valve interstitial cells is associated with higher levels of toll-like receptors 2 and 4 and enhanced expression of bone morphogenic protein 2. J Am Coll Cardiol 2009, 53(6):491-500.
81. Helske S., Lindstedt K.A., Laine M., et al. Induction of local angiotensin II producing systems in stenotic aortic valves. J Am Coll Cardiol 2004, 44:1859-1866.
82. O'Brien K.D., Shavelle D.M., Caulfield M.T., et al. Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation 2002, 106:2224-2230.
83. Holvoet P., De Keyzer D., Jacobs D.R., et al. And the metabolic syndrome. Futures Lipidol 2008, 3(6):637-649.
84. Mazzone A., Epistolato M.C., De Caterina R., et al. Neoangiogenesis, T-lymphocyte infiltration, and heat shock protein- 60 are biological hallmarks of an immunomediated inflammatory process in end-stage calcified aortic valve stenosis. J Am Coll Cardiol 2004, 43:1670-1676.
85. Ortlepp J.R., Hoffmann R., Ohme F., et al. The vitamin D receptor genotype predisposes to the development of calcific aortic valve stenosis. Heart 2001, 85:635-638.
86. Garg V., Muth A.N., Ransom J.F., et al. Mutations in Notch 1 cause aortic valve disease. Nature 2005, 437:270-274.
87. Nordström P., Glader C.A., Dahlen G., et al. Oestrogen receptor alpha gene polymorphism is related to aortic valve sclerosis in postmenopausal women. J Intern Med 2003, 254:140-146.
88. Novaro G.M., Sachar R., Pearce G.L., et al. Association between apolipoprotein E alleles and calcific valvular heart disease. Circulation 2003, 108:1804-1808.
89. Avakian S.D., Annicchino-Bizzacchi J.M., Grinberg M., et al. Apolipoproteins AI, B, and E polymorphisms in severe aortic valve stenosis. Clin Genet 2001, 60:381-384.
90. Ortlepp J.R., Pillich M., Mevissen V., et al. ApoE alleles are not associated with calcific aortic stenosis. Heart 2006, 92:1463-1466.
91. Ortlepp J.R., Schmitz F., Mevissen V., et al. The amount of calcium-deficient hexagonal hydroxyapatite in aortic valves is influenced by gender and associated with genetic polymorphisms in patients with severe calcific aortic stenosis. Eur Heart J 2004, 25:514-522.
92. Golubnitschaja O., Yeghiazaryan K., Skowasch D., et al. P21WAF1/CIP1 and 14-3-3 sigma gene expression in degenerated aortic valves: a link between cell cycle checkpoints and calcification. Amino Acids 2006, 31:309-316.
93. Kuusisto J., Räsänen K., Särkioja T., et al. Atherosclerosis-like lesions of the aortic valve are common in adults of all ages: a necropsy study. Heart 2005, 91:576-582.
94. Probst V., Le Scouarnec S., Legendre A., et al. Familial aggregation of calcific aortic valve stenosis in the western part of France. Circulation 2006, 113:856-860.
95. Roger V.L., Tajik A.J., Bailey K.R., et al. Progression of aortic stenosis in adults: new appraisal using Doppler echocardiography. Am Heart J 1990, 119:331-338.
96. Rosenhek R., Klaar U., Schemper M., et al. Mild and moderate aortic stenosis. Natural history and risk stratification by echocardiography. Eur Heart J 2004, 25:199-205.
97. Briand M., Lemieux I., Dumesnil J.G., et al. Metabolic syndrome negatively influences disease progression and prognosis in aortic stenosis. J Am Coll Cardiol 2006, 47:2229-2236.
98. Antonini-Canterin F., Hirsu M., Popescu B.A., et al. Stage-related effect of statin treatment on the progression of aortic valve sclerosis and stenosis. Am J Cardiol 2008, 102:738-742.